Genetics of idiopathic pulmonary fibrosis: From mechanistic pathways to personalised medicine

Journal of Medical Genetics

Volumn 54, Issue 2, 2017, Pages 73-83

  Spagnolo, Paolo ^a   Cottin, Vincent ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b LOUIS PRADEL HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 5B; SURFACTANT PROTEIN C; TELOMERASE;

FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEREDITY; HERITABILITY; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULAR BIOLOGY; MONOZYGOTIC TWINS; OBSERVATIONAL STUDY; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOMICS; PATHOLOGY;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMICS; GENOTYPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRECISION MEDICINE;

EID: 85007560243     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2016-103973     Document Type: Review

References (126)

1. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med2013;188:733-48.
2. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases.Am J Respir Crit Care Med2005;172:268-79.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonaryfibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med2011;183:788-824.
4. Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?Eur Respir Rev2014;23:308-19. Erratum in: Eur Respir Rev 2014;23:537.
5. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonaryfibrosis: a systematic review.Eur Respir J 2015;46:795-806.
6. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonaryfibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.Lancet Respir Med2014;2:566-72. Erratum in: Lancet Respir Med 2014;2:e12.
7. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med 1997;155:242-8.
8. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts.Lancet Respir Med2014;2:416-28.
9. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM. Long-term course and prognosis of idiopathic pulmonaryfibrosis in the new millennium.Chest2011;140:221-9.
10. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med1998;157:199-203.
11. King TE Jr, Pardo A, Selman M. Idiopathic pulmonaryfibrosis.Lancet 2011;378:1949-61.
12. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonaryfibrosis. N Engl J Med2014;370:2083-92.
13. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonaryfibrosis.N Engl J Med 2014;370:2071-82.
14. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA III, Lansdorp PM, Greider CW, Loyd JE. Telomerase mutations in families with idiopathic pulmonaryfibrosis.N Engl J Med 2007;356:1317-26.
15. Depinho RA, Kaplan KL. The Hermansky-Pudlak syndrome: report of three cases and review of pathophysiology and management considerations.Medicine (Baltimore) 1985;64:192-202.
16. Riccardi VM. Von Recklinghausen neurofibromatosis.N Engl J Med 1981;305:1617-27.
17. Malik SK, Pardee N, Martin CJ. Involvement of the lungs in tuberous sclerosis. Chest1970;58:538-40.
18. Terry RD, Sperry WM, Brodoff B. Adult lipidosis resembling Niemann-Pick's disease.Am J Pathol1954;30:263-85.
19. Schneider EL, Epstein CJ, Kaback MJ, Brandes D. Severe pulmonary involvement in adult Gaucher's disease. Report of three cases and review of the literature.Am J Med 1977;63:475-80.
20. Auwerx J, Boogaerts M, Ceuppens JL, Demedts M. Defective host defence mechanisms in a family with hypocalciuric hypercalcaemia and coexisting interstitial lung disease. Clin Exp Immunol1985;62:57-64.
21. Javaheri S, Lederer DH, Pella JA, Mark GJ, Levine BW. Idiopathic pulmonary fibrosis in monozygotic twins: the importance of genetic predisposition.Chest 1980;78:591-4.
22. Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis. A possible dysproteinemic and genetically determined disease.Am J Med 1965;39:411-21.
23. Lee HL, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, Limper AH. Familial idiopathic pulmonaryfibrosis: clinical features and outcome.Chest 2005;127:2034-41.
24. Swaye P, Van Ordstrand HS, McCormack LJ, Wolpaw SE. Familial Hamman-Rich syndrome. Report of eight cases.Dis Chest1969;55:7-12.
25. Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, Yang IV, Schwartz DA. Idiopathic pulmonaryfibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways.Physiol Rev2016;96:1567-91.
26. Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis.Eur Respir J2015;45:1717-27.
27. Kropski JA, Lawson WE, Young LR, Blackwell TS. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis.Dis Model Mech2013;6:9-17.
28. Spagnolo P, Luppi F, Cerri S, Richeldi L. Genetic testing in diffuse parenchymal lung disease. Orphanet J Rare Dis2012;7:79.
29. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.Thorax2000;55:143-6.
30. Lee HY, Seo JB, Steele MP, Schwarz MI, Brown KK, Loyd JE, Talbert JL, Schwartz DA, Lynch DA. High-resolution CT scanfindings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia.Chest 2012;142:1577-83.
31. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA III, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA. Clinical and pathologic features of familial interstitial pneumonia.Am J Respir Crit Care Med2005;172:1146-52.
32. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med2001;344:573-9.
33. Thomas AQ, Lane K, Phillips J III, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J, Roberts R, Haines J, Stahlman M, Loyd JE. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.Am J Respir Crit Care Med2002;165:1322-8.
34. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation.Am J Respir Cell Mol Biol 2005;32:521-30.
35. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, Miller GG, Loyd JE, Blackwell TS. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection.Am J Physiol Lung Cell Mol Physiol2008;294:L1119-26.
36. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle RM, Seeger W, Weaver TE, Guenther A. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med2008;178:838-46.
37. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK. Genetic defects in surfactant protein A2 are associated with pulmonaryfibrosis and lung cancer.Am J Hum Genet2009;84:52-9.
38. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. Surfactant protein A2 mutations associated with pulmonaryfibrosis lead to protein instability and endoplasmic reticulum stress.J Biol Chem 2010;285:22103-13.
39. Calado RT, Young NS. Telomere diseases.N Engl J Med2009;361:2353-65.
40. Armanios M. Telomerase and idiopathic pulmonaryfibrosis.Mutat Res 2012;730:52-8.
41. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonaryfibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA2007;104:7552-7.
42. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK. Telomere shortening in familial and sporadic pulmonaryfibrosis.Am J Respir Crit Care Med2008;178:729-37.
43. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA III, Lansdorp PM, Loyd JE, Armanios MY. Short telomeres are a risk factor for idiopathic pulmonaryfibrosis.Proc Natl Acad Sci USA 2008;105:13051-6.
44. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, Elicker BM, Ma SF, Vij R, Collard HR, Wolters PJ, Garcia CK. Effect of telomere length on survival in patients with idiopathic pulmonaryfibrosis: an observational cohort study with independent validation.Lancet Respir Med 2014;2:557-65.
45. Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Shiihara J, Ichinose M, Kojima S, Nukiwa T, Ebina M. A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonaryfibrosis.Sarcoidosis Vasc Diffuse Lung Dis2013;30:221-5.
46. Kropski JA, Mitchell DB, Markin C, Polosukhin VV, Choi L, Johnson JE, Lawson WE, Phillips JA, Cogan JD, Blackwell TS, Loyd JE. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia.Chest2014;146:e1-7.
47. Fukuhara A, Tanino Y, Ishii T, Inokoshi Y, Saito K, Fukuhara N, Sato S, Saito J, Ishida T, Yamaguchi H, Munakata M. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation.Eur Respir J2013;42:1757-9.
48. Kannengiesser C, Borie R, Revy P. Pulmonaryfibrosis associated with TINF2 gene mutation: is somatic reversion required?Eur Respir J2014;44:269-70.
49. Cogan JD, Kropski JA, Zhao M, Mitchell DB, Rives L, Markin C, Garnett ET, Montgomery KH, Mason WR, McKean DF, Powers J, Murphy E, Olson LM, Choi L, Cheng DS, Blue EM, Young LR, Lancaster LH, Steele MP, Brown KK, Schwarz MI, Fingerlin TE, Schwartz DA, Lawson WE, Loyd JE, Zhao Z, Phillips JA III, Blackwell TS. Rare variants in RTEL1 are associated with familial interstitial pneumonia.Am J Respir Crit Care Med 2015;191:646-55.
50. Stuart BD, Choi J, Zaidi S, Xing C, Holohan B, Chen R, Choi M, Dharwadkar P, Torres F, Girod CE, Weissler J, Fitzgerald J, Kershaw C, Klesney-Tait J, Mageto Y, Shay JW, Ji W, Bilguvar K, Mane S, Lifton RP, Garcia CK. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonaryfibrosis and telomere shortening.Nat Genet2015;47:512-17.
51. Theall KP, McKasson S, Mabile E, Dunaway LF, Drury SS. Early hits and long-term consequences: tracking the lasting impact of prenatal smoke exposure on telomere length in children. Am J Public Health2013;103(Suppl 1):S133-35.
52. GoldmanF, BouarichR, KulkarniS, FreemanS, DuHY, HarringtonL, Mason PJ, Londoño-Vallejo A, Bessler M. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci USA 2005;102:17119-24.
53. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, Rosenblatt RL, Girod CE, Garrity ER, Xing C, Garcia CK. Telomere lengths, pulmonaryfibrosis and telomerase (TERT) mutations.PLoS ONE2010;5:e10680.
54. Fahy JV, Dickey BF. Airway mucus function and dysfunction.N Engl J Med 2010;363:2233-47.
55. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A common MUC5B promoter polymorphism and pulmonaryfibrosis. N Engl J Med2011;364:1503-12.
56. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science2005;308:385-9.
57. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, Richards TJ, Juan-Guardela BM, Vij R, Han MK, Martinez FJ, Kossen K, Seiwert SD, Christie JD, Nicolae D, Kaminski N, Garcia JG. Genetic variants associated with idiopathic pulmonaryfibrosis susceptibility and mortality: a genome-wide association study.Lancet Respir Med2013;1:309-17.
58. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, Airo P, Matucci-Cerinic M, Wallaert B, Israel-Biet D, Cadranel J, Cottin V, Gazal S, Peljto AL, Varga J, Schwartz DA, Valeyre D, Grandchamp B. The MUC5B variant is associated with idiopathic pulmonaryfibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS ONE2013;8: e70621.
59. Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Lindahl GE, Renzoni EA. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lungfibrosis in systemic sclerosis or sarcoidosis.Thorax2013;68:436-41.
60. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.N Engl J Med2011;364:1576-7.
61. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, Lee JS, Ji W, Schwarz MI, Yang IV, Schwartz DA, Fingerlin TE. The MUC5B promoter polymorphism is associated with idiopathic pulmonaryfibrosis in a Mexican cohort but is rare among Asian ancestries.Chest2015;147:460-4.
62. Horimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, Kohno N, Guzman J, Costabel U. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis.Respirology2015;20:439-44.
63. Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA. The pulmonaryfibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.Chest2012;142:1584-8.
64. Seibold MA, Smith RW, Urbanek C, Groshong SD, Cosgrove GP, Brown KK, Schwarz MI, Schwartz DA, Reynolds SD. The idiopathic pulmonaryfibrosis honeycomb cyst contains a mucociliary pseudostratified epithelium.PLoS ONE 2013;8:e58658.
65. Nakano Y, Yang IV, Walts AD, Watson AM, Helling BA, Fletcher AA, Lara AR, Schwarz MI, Evans CM, Schwartz DA. MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med2016;193:464-6.
66. Zhu L, Wang L, Luo X, Zhang Y, Ding Q, Jiang X, Wang X, Pan Y, Chen Y. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-β signaling pathway.J Biol Chem 2012;287:39653-63.
67. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA. Genome-wide association study identifies multiple susceptibility loci for pulmonaryfibrosis.Nat Genet2013;45:613-20. Erratum in: Nat Genet 2013;45:1409.
68. Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA. Genome-wide imputation study identifies novel HLA locus for pulmonaryfibrosis and potential role for auto-immunity infibrotic idiopathic interstitial pneumonia. BMC Genet2016;17:74.
69. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms.Am J Respir Crit Care Med2000;162:755-8.
70. Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ, van den Bosch JM, Grutters JC. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis.Clin Exp Immunol2011;166:346-51.
71. Ahn MH, Park BL, Lee SH, Park SW, Park JS, Kim DJ, Jang AS, Park JS, Shin HK, Uh ST, Kim YK, Kim YW, Han SK, Jung KS, Lee KY, Jeong SH, Park JW, Choi BW, Park IW, Chung MP, Shin HD, Song JW, Kim DS, Park CS, Shim YS. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode.Respir Res2011;12:73.
72. Pulkkinen V, Bruce S, Rintahaka J, Hodgson U, Laitinen T, Alenius H, Kinnula VL, Myllärniemi M, Matikainen S, Kere J. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses.FASEB J 2010;24:1167-77.
73. O'Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, Simpson AJ, Millar AB, McGrath EE, Whyte MK, Hirani N, Hogaboam CM, Donnelly SC. The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med2013;188:1442-50.
74. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y, Pirfenidone Clinical Study Group. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonaryfibrosis.J Med Genet 2008;45:654-6.
75. Korthagen NM, van Moorsel CH, Barlo NP, Kazemier KM, Ruven HJ, Grutters JC. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis.PLoS ONE2012;7:e30442.
76. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, Rosen GD, Rosas IO, Dacic S, Ocak I, Fuhrman CR, Cuenco KT, Smith MA, Jacobs SS, Zeevi A, Morel PA, Pilewski JM, Valentine VG, Gibson KF, Kaminski N, Sciurba FC, Zhang Y, Duncan SR. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonaryfibrosis.PLoS ONE2011;6:e14715.
77. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, van Es HW, van den Bosch JM, Grutters JC. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonaryfibrosis in a Dutch cohort.Am J Respir Crit Care Med2010;182:1419-25.
78. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, Roldan J, Scott TA, Blackwell TS, Phillips JA III, Loyd JE, du Bois RM. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF.Thorax2004;59:977-80.
79. Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, Theruvath I, Pison U, Seeger W, Guenther A, Witt H. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias.EurRespirJ 2007;29:134-7.
80. Alder JK, Stanley SE, Wagner CL, Hamilton M, Hanumanthu VS, Armanios M. Exome sequencing identifies mutant TINF2 in a family with pulmonaryfibrosis. Chest2015;147:1361-8.
81. Campo I, Zorzetto M, Mariani F, Kadija Z, Morbini P, Dore R, Kaltenborn E, Frixel S, Zarbock R, Liebisch G, Hegermann J, Wrede C, Griese M, Luisetti M. A large kindred of pulmonaryfibrosis associated with a novel ABCA3 gene variant.Respir Res2014;15:43.
82. Epaud R, Delestrain C, Louha M, Simon S, Fanen P, Tazi A. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations.Eur Respir J 2014;43:638-41.
83. Son JY, Kim SY, Cho SH, Shim HS, Jung JY, Kim EY, Lim JE, Park BH, Kang YA, Kim YS, Kim SK, Chang J, Park MS. TGF-beta1 T869C polymorphism may affect susceptibility to idiopathic pulmonaryfibrosis and disease severity.Lung 2013;191:199-205.
84. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, Campistol JM, Mullol J, Picado C. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med2003;168:431-5.
85. Alder JK, Parry EM, Yegnasubramanian S, Wagner CL, Lieblich LM, Auerbach R, Auerbach AD, Wheelan SJ, Armanios M. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene.Hum Mutat 2013;34:1481-5.
86. Lawson WE, Polosukhin VV, Stathopoulos GT, Zoia O, Han W, Lane KB, Li B, Donnelly EF, Holburn GE, Lewis KG, Collins RD, Hull WM, Glasser SW, Whitsett JA, Blackwell TS. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin.Am J Pathol 2005;167:1267-77.
87. Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D. Telomerase in alveolar epithelial development and repair.Am J Physiol Lung Cell Mol Physiol2000;279: L1191-8.
88. Lee J, Reddy R, Barsky L, Scholes J, Chen H, Shi W, Driscoll B. Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice. Am J Physiol Lung Cell Mol Physiol 2009;296:L57-70.
89. Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, Walsh MF, Sussan T, Biswal S, Mitzner W, Tuder RM, Armanios M. Telomere length is a determinant of emphysema susceptibility.Am J Respir Crit Care Med2011;184:904-12.
90. Morris A, Gibson K, Collman RG. The lung microbiome in idiopathic pulmonary fibrosis: what does it mean and what should we do about it?Am J Respir Crit Care Med2014;190:850-2.
91. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway defence.Nature2014;505:412-16.
92. Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis.Proc Am Thorac Soc2012;9:120-5.
93. Kolb M, White ES, Gauldie J. Mucking around in the genome: MUC5B in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2016;193:355-7.
94. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonaryfibrosis. Annu Rev Pathol2014;9:157-79.
95. Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2014;189:770-8.
96. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care.Am J Respir Crit Care Med2012;185:1147-53.
97. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, Ross JC, San José Estépar R, Murphy E, Steele MP, Loyd JE, Schwarz MI, Fingerlin TE, Rosas IO, Washko GR, O'Connor GT, Schwartz DA. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med2013;368:2192-200.
98. Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, Nishino M, Zazueta OE, Kurugol S, Ross JC, San José Estépar R, Schwartz DA, Rosas IO, Washko GR, O'Connor GT, Hunninghake GM. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med2016;194:1514-22.
99. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the MultiEthnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med2009;180:407-14.
100. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estépar RS, Lynch DA, Brehm JM, Andriole KP, Diaz AA, Khorasani R, D'Aco K, Sciurba FC, Silverman EK, Hatabu H, Rosas IO, COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med2011;364:897-906.
101. Sverzellati N, Guerci L, Randi G, Calabr 0 o E, La Vecchia C, Marchianò A, Pesci A, Zompatori M, Pastorino U. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J2011;38:392-400.
102. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE Jr, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonaryfibrosis: clinical behavior and gene expression pattern.PLoS ONE2007;2:e482.
103. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Acute exacerbation of idiopathic pulmonaryfibrosis: an international working group report.Am J Respir Crit Care Med2016;194:265-75.
104. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonaryfibrosis.JAMA 2013;309:2232-9.
105. Chung JH, Peljto AL, Chawla A, Talbert JL, McKean DF, Rho BH, Fingerlin TE, Schwarz MI, Schwartz DA, Lynch DA. CT imaging phenotypes of pulmonary fibrosis in the MUC5B promoter site polymorphism.Chest 2016;149:1215-22.
106. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors.Nat Immunol2010;11:373-84.
107. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I, IPFnet Investigators. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med 2015;192:1475-82.
108. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.N Engl J Med2012;366:1968-77.
109. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G, Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.N Engl J Med2014;370:2093-101.
110. Oldham JM, Noth I, Martinez FJ. Pharmacogenetics and interstitial lung disease. Curr Opin Pulm Med2016;22:456-65.
111. Silhan LL, Shah PD, Chambers DC, Snyder LD, Riise GC, Wagner CL, Hellström-Lindberg E, Orens JB, Mewton JF, Danoff SK, Arcasoy MO, Armanios M. Lung transplantation in telomerase mutation carriers with pulmonaryfibrosis.Eur Respir J2014;44:178-87.
112. Borie R, Kannengiesser C, Hirschi S, Le Pavec J, Mal H, Bergot E, Jouneau S, Naccache JM, Revy P, Boutboul D, Peffault de la Tour R, Wemeau-Stervinou L, Philit F, Cordier JF, Thabut G, Crestani B, Cottin V, Groupe d'Etudes et de Recherche sur les Maladies"Orphelines"Pulmonaires (GERM"O"P). Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.J Heart Lung Transplant 2015;34:538-46.
113. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.Bone Marrow Transplant 2011;46:98-104.
114. Borie R, Kannengiesser C, Nathan N, Crestani B. Genetics. In Idiopathic pulmonary fibrosis.ERS Monogr2016;71:1-15.
115. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missingheritability of complex diseases.Nature 2009;461:747-53.
116. Yang IV, Schwartz DA. The next generation of complex lung genetic studies.Am J Respir Crit Care Med 2012;186:1087-94.
117. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright VP, Nana-Sinkam SP, Piper MG, Marsh CB. Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonaryfibrosis. Am J Respir Crit Care Med2013;187:397-405.
118. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy.Nature2004;429:457-63.
119. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonaryfibrosis.Transl Res 2015;165:48-60.
120. Selman M, López-Otín C, Pardo A. Age-driven developmental drift in the pathogenesis of idiopathic pulmonaryfibrosis.Eur Respir J 2016;48:538-52.
121. Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer.PLoS ONE2012;7:e32921.
122. Selman M, Pardo A, Kaminski N. Idiopathic pulmonaryfibrosis: aberrant recapitulation of developmental programs? PLoS Med2008;5:e62.
123. Sanders YY, Hagood JS, Liu H, Zhang W, Ambalavanan N, Thannickal VJ. Histone deacetylase inhibition promotesfibroblast apoptosis and ameliorates pulmonary fibrosis in mice.Eur Respir J2014;43:1448-58.
124. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence.Free Radic Biol Med 2015;79:197-205.
125. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, Bray M, Zhang K, Thannickal VJ, Hagood JS. Altered DNA methylation profile in idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med2012;186:525-35.
126. Yang IV, Pedersen BS, Rabinovich E, Hennessy CE, Davidson EJ, Murphy E, Guardela BJ, Tedrow JR, Zhang Y, Singh MK, Correll M, Schwarz MI, Geraci M, Sciurba FC, Quackenbush J, Spira A, Kaminski N, Schwartz DA. Relationship of DNA methylation and gene expression in idiopathic pulmonaryfibrosis.Am J Respir Crit Care Med 2014;190:1263-72.